ZUG, Switzerland

楚格，瑞士

and

和

BOSTON

波士顿

,

，

Sept. 09, 2025

2025年9月9日

(GLOBE NEWSWIRE) --

（环球新闻社）--

CRISPR Therapeutics

CRISPR疗法

(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9

(Nasdaq: CRSP)，一家专注于为严重疾病开发基于基因的变革性药物的生物制药公司，今天宣布了一项最新的口头报告，重点介绍了公司正在研究的CRISPR/Cas9一期临床数据。

in vivo

体内

gene editing therapy, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) for cardiovascular and cardiometabolic disease, will be presented at the

基因编辑疗法CTX310™，靶向血管生成素相关蛋白3（ANGPTL3），用于心血管和心脏代谢疾病，将在会议上展示。

American Heart Association

美国心脏协会

(AHA) Scientific Sessions 2025, taking place

(AHA) 2025年科学会议，即将举行

November 7

11月7日

– 10, 2025, in

– 2025年10月，在

New Orleans, Louisiana

路易斯安那州新奥尔良市

. Additionally, the Company will present a poster presentation on CTX340™, its

此外，公司将展示一幅关于CTX340™的海报，其

in vivo

体内

preclinical program targeting angiotensinogen (AGT) for the treatment of refractory hypertension.

针对血管紧张素原（AGT）治疗难治性高血压的临床前项目。

Abstract Title

摘要标题

: First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

：针对ANGPTL3的CRISPR-Cas9基因编辑疗法的首次人体一期临床试验

Abstract Number:

摘要编号：

4392851

4392851

Session Type:

会话类型：

Late-Breaking Science (Oral Presentation)

最新突破性科学（口头报告）

Session Title

会议标题

: LBS.01 Groundbreaking Trials in Cardiometabolic Therapeutics

LBS.01 心脏代谢治疗领域的开创性试验

Session Date and Time:

会话日期和时间：

Saturday, November 8, 2025,

2025年11月8日，星期六，

8:30 a.m. CST

上午8点30分（中部标准时间）

Abstract Title

摘要标题

:

：

In vivo

体内

gene editing of Angiotensinogen in hepatocytes safely and potently reduces blood pressure in preclinical models

肝细胞中血管紧张素原的基因编辑安全且有效地降低了临床前模型中的血压

Abstract Number:

摘要编号：

4391815

4391815

Session Type:

会话类型：

Late-Breaking Basic Science (Poster Presentation)

最新基础科学（海报展示）

Session Title:

会议标题：

LBBS.APS.01 Precision Interventions for the Failing Heart: Genetic, Metabolic, and Immune Frontiers

LBBS.APS.01 精准干预心力衰竭：遗传、代谢和免疫前沿

Session Date and Time:

会议日期和时间：

Saturday, November 8, 2025,

2025年11月8日，星期六，

2:30 p.m. CST

下午2点30分（中部标准时间）

The accepted abstract titles are available online on the

已接受的摘要标题可在线获取。

AHA website

美国心脏协会网站

. The data in the abstracts and presentations are embargoed until the date and time of presentation. A copy of each presentation will be available at

摘要和演示文稿中的数据在演示的日期和时间之前处于禁发状态。每份演示文稿的副本将在

www.crisprtx.com

www.crisprtx.com

once the presentation concludes.

一旦演示结束。

About

关于

In Vivo

体内

Programs

程序

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) platform for the delivery of CRISPR/Cas9 to the liver. The Company’s

CRISPR Therapeutics 已建立了一个专有的脂质纳米颗粒（LNP）平台，用于将 CRISPR/Cas9 递送到肝脏。公司

in vivo

体内

portfolio includes its lead investigational programs, CTX310 (directed towards angiopoietin-related protein 3 (

产品组合包括其主要研究项目CTX310（针对血管生成素相关蛋白3（

ANGPTL3

血管生成素样蛋白3

)) and CTX320 (directed towards

)) 和 CTX320（针对

LPA

LPA

, the gene encoding apolipoprotein(a) (apo(a)), a major component of lipoprotein(a) [Lp(a)]). Both are validated therapeutic targets for cardiovascular and cardiometabolic disease. CTX310 and CTX320 are in ongoing clinical trials in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hypertriglyceridemia, and in patients with elevated lipoprotein(a), respectively.

，该基因编码载脂蛋白(a)（apo(a)），是脂蛋白(a) [Lp(a)]的主要成分）。二者均为心血管和心脏代谢疾病的有效治疗靶点。CTX310和CTX320正在杂合子家族性高胆固醇血症、纯合子家族性高胆固醇血症、混合型血脂异常或严重高甘油三酯血症患者中进行临床试验，并分别在脂蛋白(a)升高的患者中开展试验。

In addition, the Company’s research and preclinical development candidates include CTX340 and CTX450, targeting angiotensinogen (.

此外，公司研发和临床前开发的候选药物包括CTX340和CTX450，靶向血管紧张素原。

AGT

agt

) for refractory hypertension and 5’-aminolevulinate synthase 1 (

) 用于难治性高血压和5'-氨基乙酰丙酸合成酶1 (

ALAS1

ALAS1

) for acute hepatic porphyria (AHP), respectively.

) 分别用于急性肝卟啉症 (AHP)。

About CRISPR Therapeutics

关于CRISPR治疗学

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases.

自从十多年前成立以来，CRISPR Therapeutics已经从一家推进基因编辑项目的研究型公司发展成为庆祝首个基于CRISPR疗法历史性获批的领导者。该公司拥有涵盖多种疾病领域的产品候选组合，包括血红蛋白病、肿瘤学、再生医学、心血管、自身免疫和罕见病。

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY.

2018年，CRISPR Therapeutics公司将首个CRISPR/Cas9基因编辑疗法推进到临床，以研究镰状细胞病和依赖输血的β地中海贫血的治疗。从2023年底开始，CASGEVY。

®

®

(exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.

(exagamglogene autotemcel [exa-cel]) 已在多个国家获批用于治疗符合资格的患者。荣获诺贝尔奖的CRISPR技术已经彻底改变了生物医学研究，并代表了一种强大且经过临床验证的方法，有望创造出一类具有潜在变革性的新药物。

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

为了加速和扩大其努力，CRISPR Therapeutics 已与包括 Vertex Pharmaceuticals 在内的领先公司建立了战略合作伙伴关系。CRISPR Therapeutics AG 总部位于瑞士楚格，其全资美国子公司 CRISPR Therapeutics, Inc. 以及研发业务基地分别位于马萨诸塞州波士顿和加利福尼亚州旧金山。

To learn more, visit .

要了解更多信息，请访问。

www.crisprtx.com

www.crisprtx.com

.

。

CRISPR THERAPEUTICS

CRISPR治疗学

®

®

standard character mark and design logo CTX310™ and CTX340™ are trademarks and registered trademarks of CRISPR Therapeutics AG.

标准字符标记和设计标志 CTX310™ 和 CTX340™ 是 CRISPR Therapeutics AG 的商标和注册商标。

CRISPR Therapeutics Forward-Looking Statement

CRISPR Therapeutics 前瞻性声明

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

本新闻稿中包含的关于非历史事实的陈述是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。由于此类声明受到风险和不确定性的影响，实际结果可能与这些前瞻性声明中表达或暗示的结果有重大差异。

Such statements include, but are not limited to, statements regarding any or all of the following: (i) .

这些声明包括但不限于以下任何或所有内容的声明：(i) 。

CRISPR Therapeutics

CRISPR治疗公司

preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation and above-described abstracts and any associated poster, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies.

临床前研究、临床试验以及渠道产品和项目，包括但不限于生产能力、这些研究和试验的状态、向新适应症的潜在扩展以及关于数据、安全性和有效性的总体预期；(ii) 上述口头报告和上述摘要以及任何相关海报中包含的数据，以及利用正在进行和计划中的临床试验数据来设计和启动更多临床试验的能力；以及 (iii) 基因编辑技术及疗法（包括CRISPR/Cas9及其他技术）的治疗价值、开发和商业潜力。

Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in .

可能导致前瞻性陈述具有不确定性的风险包括但不限于“风险因素”标题下讨论的风险和不确定性。

CRISPR Therapeutics

CRISPR Therapeutics

most recent annual report on Form 10-K and in any other subsequent filings made by

最新的年度报告表格10-K以及任何其他后续提交的文件中

CRISPR Therapeutics

CRISPR疗法

with the

随着

U.S. Securities and Exchange Commission

美国证券交易委员会

. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law..

现有和潜在投资者被警告不要对这些前瞻性陈述施加过度依赖，这些陈述仅在其作出之日有效。我们否认有任何义务或承诺更新或修改本新闻稿中包含的任何前瞻性陈述，除非法律要求的范围内。

Investor Contact:

投资者联系：

+1-617-307-7503

+1-617-307-7503

ir@crisprtx.com

投资者关系@克里丝普特克斯公司.康母

Media Contact:

媒体联系人:

+1-617-315-4493

+1-617-315-4493

media@crisprtx.com

媒体@crisprtx.com

Source: CRISPR Therapeutics AG

来源：CRISPR Therapeutics AG